近期，被称为“美妆茅台”的A股上市公司爱美客（300896.SZ）因大股东及高管频繁减持股份引发市场广泛关注和争议。爱美客主营医美玻尿酸产品，凭借高毛利率和强劲增长，股价一度飙升，被投资者誉为“医美茅”或“美妆茅台”。然而，自2021年上市以来，公司多位原始股东、董监高陆续公告减持计划，累计套现金额高达数十亿元。部分投资者质疑其减持节奏过快、信息披露不充分，甚至怀疑公司基本面是否支撑当前高估值。对此，爱美客回应称减持属股东个人资金安排，不影响公司正常经营。但市场情绪仍受冲击，股价出现明显波动。分析人士指出，高估值叠加频繁减持，可能削弱投资者信心，尤其在医美行业监管趋严、竞争加剧的背景下，企业需更注重长期价值传递而非短期套利。此次事件也再次引发对A股“造富效应”与股东责任平衡的讨论。
Recently, Aimeike (stock code: 300896.SZ), dubbed the ‘Moutai of the beauty industry,’ has sparked widespread controversy due to frequent share sell-offs by major shareholders and executives. Specializing in hyaluronic acid-based medical aesthetic products, Aimeike has enjoyed high gross margins and rapid growth since its listing, earning it nicknames like ‘Medical Aesthetic Moutai.’ However, since its IPO in 2021, numerous founding shareholders and senior management have announced successive plans to reduce their stakes, collectively cashing out billions of RMB. Some investors have raised concerns over the pace of these sell-offs and insufficient disclosure, questioning whether the company’s fundamentals truly justify its lofty valuation. Aimeike responded that the sales are part of individual shareholders’ financial planning and will not affect normal operations. Nonetheless, market sentiment has been rattled, leading to notable stock price volatility. Analysts warn that high valuations combined with repeated insider selling could erode investor confidence—especially as China tightens regulations and intensifies competition in the medical aesthetics sector. The episode has reignited broader debates about balancing wealth creation on China’s A-share market with shareholder accountability.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/10640.html